Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
PCSK9 encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. Additionally we are shipping PCSK9 Kits (74) and PCSK9 Proteins (64) and many more products for this protein.
Showing 10 out of 160 products:
Human Polyclonal PCSK9 Primary Antibody for ChIP, IHC (p) - ABIN268772
Cohen, Pertsemlidis, Kotowski, Graham, Garcia, Hobbs: Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. in Nature genetics 2005
Show all 10 Pubmed References
Human Polyclonal PCSK9 Primary Antibody for ELISA, WB - ABIN4347756
Kwon, Lagace, McNutt, Horton, Deisenhofer: Molecular basis for LDL receptor recognition by PCSK9. in Proceedings of the National Academy of Sciences of the United States of America 2008
Human Polyclonal PCSK9 Primary Antibody for ELISA, IP - ABIN4347755
Lalanne, Lambert, Amar, Chétiveaux, Zaïr, Jarnoux, Ouguerram, Friburg, Seidah, Brewer, Krempf, Costet: Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells. in Journal of lipid research 2005
Human Polyclonal PCSK9 Primary Antibody for IF (p), IHC (p) - ABIN761831
Jia, Song, Yang, Ma, Li, Lu, Cao, Zhang, Zhu, Wang, Leng, Cao, Du, Xu: Effects of Tanshinone IIA on the modulation of miR‑33a and the SREBP‑2/Pcsk9 signaling pathway in hyperlipidemic rats. in Molecular medicine reports 2016
Rare variants of APOB (show APOB Antibodies) or PCSK9 were identified in nine of the 22 study patients with extremely low LDL-C levels
PCSK9 plays a direct role on Abca1 (show ABCA1 Antibodies)-mediated cholesterol efflux through a downregulation of Abca1 (show ABCA1 Antibodies) gene and Abca1 (show ABCA1 Antibodies) protein expression. This extrahepatic effect may influence relevant steps in the pathogenesis of atherosclerosis, such as foam cell formation.
kidney function per se does not impact significantly PCSK9 metabolism
Sirolimus therapy in heart transplant patients is associated with elevation in PCSK9 levels which is not associated with sirolimus-induced hypercholesterolemia.
PCSK9 inhibits lipoprotein(a) clearance through the LDLR (show LDLR Antibodies).
PCSK9 variants reduced fasting LDL-C as well as fasting triglycerides.
Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR (show LDLR Antibodies) mutations modifies the phenotype of familial hypercholesterolemia
PCSK9 associated with Familial Hypercholesterolemia and Polygenic Hypercholesterolemia in patients with Acute Coronary Syndrome , age =65 years, and LDL-C levels >/=160 mg/dl.
Results clearly that PCSK9 serum concentrations were associated to liver function and mortality, pointed to the disturbance of steroid regulation in patients with end-stage liver disease and an association of such disturbance with mortality. Further studies are required to acquire a more detailed understanding of the role of PCSK9 in liver-related mortality.
Use Crispr-Cas (show CSE1L Antibodies) system to introduce nonsense variants into PCSK9 to lower blood cholesterol levels.
Use Crispr-Cas (show CTNND1 Antibodies) system to introduce nonsense variants into PCSK9 to lower blood cholesterol levels.
Studied the combination model of a single AAV-PCSK9 injection, high-fat diet, and partial carotid ligation which induces robust atherosclerosis in the flow-disturbed carotid artery within 3 weeks in C57 mice, and results suggest this is a quick and convenient model to study atherosclerosis and mechanisms using any knockout or transgenic mice without having to generate double knockouts.
These observations suggest positive feedback interplay between SMC (show DYM Antibodies)-derived PCSK9 and mtDNA damage in the proinflammatory milieu involving mtROS. This interaction results in cellular injury, characterized by apoptosis-a hallmark of atherosclerosis.
AdipoR activation by agonists regulated PCSK9 expression and inhibits atherosclerosis in apoE (show APOE Antibodies)(-/-) mice.
Adeno (show ADORA2A Antibodies)-associated virus mediated infection with a mouse PCSK9 gain-of-function mutation is a rapid, easy, and efficient approach for inducing hypercholesterolemia and promoting abdominal aortic aneurysms in C57BL/6 mice infused with angiotensin II.
conditions that cause ER stress regardless of their ability to dysregulate ER Ca(2 (show CA2 Antibodies)+) inhibit PCSK9 secretion, thereby reducing PCSK9-mediated LDLR (show LDLR Antibodies) degradation and promoting LDLR (show LDLR Antibodies)-dependent hepatic cholesterol uptake.
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor (show LDLR Antibodies) Degradation.
PCSK9 increases hepatic lipid and lipoprotein production via apoE (show APOE Antibodies)- and LDLR (show LDLR Antibodies)-dependent mechanisms
Podocyte damage triggers marked inductions in plasma PCSK9, and knockout of Pcsk9 ameliorates dyslipidemia in a mouse model of nephrotic syndrome.
This gene encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. The encoded protein is synthesized as a soluble zymogen that undergoes autocatalytic intramolecular processing in the endoplasmic reticulum. The protein may function as a proprotein convertase. This protein plays a role in cholesterol homeostasis and may have a role in the differentiation of cortical neurons. Mutations in this gene have been associated with a third form of autosomal dominant familial hypercholesterolemia (HCHOLA3).
proprotein convertase subtilisin/kexin type 9
, convertase subtilisin/kexin type 9 preproprotein
, neural apoptosis regulated convertase 1
, subtilisin/kexin-like protease PC9
, convertase subtilisin
, neural apoptosis-regulated convertase 1
, proprotein convertase 9
, proprotein convertase PC9
, proprotein convertase subtilisin/kexin type 9 preproprotein
, Proprotein convertase 9
, Subtilisin/kexin-like protease PC9